GERN - PDUFA Data Release on 16/06/2024

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Recent Activity
Blockbuys: See the screenshot in the chart.

Expecting: A pre run-up into the data release on 16/06/2024.

Key Technical Levels
Breakout Zone: $3.70 - $4.00 (Very strong resistance)

Resistance Points:

$4.30
$4.60

Surpassing these levels could signal a positive trend. Consider taking profits at these stages to realize gains.

Trading Strategy

Take Profit (TP): Target $5.00 to capitalize on the anticipated price gap closure (this likely only works if the data release is positive).

Stop Loss (SL): Set at under $3.50 to mitigate potential losses.

Chart Analysis
Please refer to the attached chart for detailed analysis of price trends and movements.

Trading Advisory
Exercise caution and consider market conditions and your own risk tolerance when trading. Conduct comprehensive research or consult with a financial advisor before engaging in trading activities.

Disclaimer
This content is for informational purposes only and should not be considered financial advice.

交易結束：目標達成

hugeee smell - hit 5.15 pre market.

Buy Rating Reaffirmed for Geron Corp with FDA Approval of Rytelo, Foreseeing $1.2 Billion Peak Sales

we might see higher long-term